• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一线β受体阻滞剂单药治疗高血压患者的综合疗效和安全性比较：一项大规模多中心观察性研究。

Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.

机构信息

Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (S.C.Y., R.W.P.).

Department of Preventive Medicine and Public Health (S.C.Y.), Yonsei University College of Medicine, Seoul, Korea.

出版信息

Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29.

DOI:10.1161/HYPERTENSIONAHA.120.16402
PMID:33775125
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC8035236/
Abstract

[Figure: see text].

摘要

[图：见正文]。

相似文献

1
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.一线β受体阻滞剂单药治疗高血压患者的综合疗效和安全性比较：一项大规模多中心观察性研究。
Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29.
2
Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes.奈必洛尔与阿替洛尔对II型糖尿病高血压患者血压及胰岛素敏感性的比较效应
J Hum Hypertens. 1997 Nov;11(11):753-7. doi: 10.1038/sj.jhh.1000533.
3
Use of carvedilol in hypertension: an update.卡维地洛在高血压治疗中的应用：最新进展
Vasc Health Risk Manag. 2012;8:307-22. doi: 10.2147/VHRM.S31578. Epub 2012 May 18.
4
[Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].单纯收缩期高血压。“血管紧张素Ⅱ1型受体阻滞剂优于β受体阻滞剂”
MMW Fortschr Med. 2002 Sep 19;144(38):14.
5
Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.新型血管扩张性β受体阻滞剂卡维地洛与阿替洛尔治疗轻至中度原发性高血压的比较。
Am J Hypertens. 1994 Feb;7(2):129-36. doi: 10.1093/ajh/7.2.129.
6
Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.奈必洛尔与阿替洛尔对原发性高血压的降压及β1-肾上腺素能受体拮抗作用比较
Clin Exp Hypertens. 1993 May;15(3):501-9. doi: 10.3109/10641969309041625.
7
[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].阿替洛尔/硝苯地平联合用药：低剂量协同双药疗法治疗动脉高血压的疗效及耐受性
Drugs. 1998;56 Suppl 2:31-43. doi: 10.2165/00003495-199856002-00004.
8
Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study.不同初始β受体阻滞剂对治疗持续性的影响：阿替洛尔与新一代β受体阻滞剂的一项基于人群的研究
Cardiovasc Ther. 2016 Aug;34(4):268-75. doi: 10.1111/1755-5922.12197.
9
Nebivolol: a third-generation beta-blocker for hypertension.奈必洛尔：一种用于治疗高血压的第三代β受体阻滞剂。
Clin Ther. 2009 Mar;31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007.
10
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.卡维地洛与阿替洛尔单用及与氢氯噻嗪联用的安全性和降压疗效。
Eur J Clin Pharmacol. 1990;38 Suppl 2:S143-6. doi: 10.1007/BF01409485.

引用本文的文献

1
Inappropriate use of propranolol among medical students in Palestine: cross-sectional study.巴勒斯坦医学生中普萘洛尔的不当使用：横断面研究。
BMC Med Educ. 2025 Apr 28;25(1):624. doi: 10.1186/s12909-025-07094-x.
2
The Influence of Recreational Hiking on the Prevalence of Cardiovascular and Psychiatric Diseases Among Population of Republic of Serbia.休闲徒步对塞尔维亚共和国人群心血管疾病和精神疾病患病率的影响。
Healthcare (Basel). 2025 Mar 20;13(6):680. doi: 10.3390/healthcare13060680.
3
Symptoms and Conditions in Children and Adults up to 90 Days after SARS-CoV-2 Infection: A Retrospective Observational Study Utilizing the Common Data Model.

本文引用的文献

1
Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND).网络数据库中大规模证据生成与评估的原则（LEGEND）。
J Am Med Inform Assoc. 2020 Aug 1;27(8):1331-1337. doi: 10.1093/jamia/ocaa103.
2
Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study.大规模证据生成与评估网络数据库（LEGEND）：以高血压为案例研究评估其有效性。
J Am Med Inform Assoc. 2020 Aug 1;27(8):1268-1277. doi: 10.1093/jamia/ocaa124.
3
Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials.
新冠病毒感染后90天内儿童和成人的症状与病症：一项利用通用数据模型的回顾性观察研究
J Clin Med. 2024 May 15;13(10):2911. doi: 10.3390/jcm13102911.
4
OHDSI Standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization.OHDSI 标准化词汇表-用于国际数据协调的大规模集中参考本体。
J Am Med Inform Assoc. 2024 Feb 16;31(3):583-590. doi: 10.1093/jamia/ocad247.
5
Utilization patterns of cardiovascular medications in patients with diabetes mellitus; a retrospective cross-sectional study, 2013-17.糖尿病患者心血管药物的使用模式：一项 2013-2017 年的回顾性横断面研究。
Daru. 2023 Dec;31(2):259-266. doi: 10.1007/s40199-023-00481-z. Epub 2023 Oct 17.
6
Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline.TRAnsPARENT Reporting of observational studies Emulating a Target trial (TARGET) 指南的制定。
BMJ Open. 2023 Sep 12;13(9):e074626. doi: 10.1136/bmjopen-2023-074626.
7
The correlation between different antihypertensive treatments and prognosis of cardiovascular disease in hypertensive patients.不同降压治疗与高血压患者心血管疾病预后的相关性。
BMC Cardiovasc Disord. 2023 Jul 22;23(1):369. doi: 10.1186/s12872-023-03381-x.
8
Sex differences in the renin-angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and kidney diseases.肾素-血管紧张素-醛固酮系统中的性别差异及其在高血压、心血管疾病和肾脏疾病中的作用。
Front Cardiovasc Med. 2023 Jun 19;10:1198090. doi: 10.3389/fcvm.2023.1198090. eCollection 2023.
9
Hallmarks of cardiovascular ageing.心血管衰老的特征
Nat Rev Cardiol. 2023 Nov;20(11):754-777. doi: 10.1038/s41569-023-00881-3. Epub 2023 May 16.
10
National Heart Center/Saudi Heart Association 2023 Guidelines on the Management of Hypertension.国家心脏中心/沙特心脏协会2023年高血压管理指南。
J Saudi Heart Assoc. 2023 Mar 3;35(1):16-39. doi: 10.37616/2212-5043.1328. eCollection 2023.
β受体阻滞剂治疗高血压：随机对照试验的概述与荟萃分析
J Hypertens. 2020 Sep;38(9):1669-1681. doi: 10.1097/HJH.0000000000002523.
4
Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.2005 - 2016年美国成年人抗高血压药物单一疗法和联合使用趋势，美国国家健康与营养检查调查
Hypertension. 2020 Apr;75(4):973-981. doi: 10.1161/HYPERTENSIONAHA.119.14360. Epub 2020 Mar 9.
5
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.比较氯噻酮与氢氯噻嗪治疗高血压的心血管和安全性结局。
JAMA Intern Med. 2020 Apr 1;180(4):542-551. doi: 10.1001/jamainternmed.2019.7454.
6
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.一线降压药类别全面比较效果和安全性：系统的、多国的、大规模分析。
Lancet. 2019 Nov 16;394(10211):1816-1826. doi: 10.1016/S0140-6736(19)32317-7. Epub 2019 Oct 24.
7
Prescribing Patterns of Antihypertensives for Treatment-Naïve Patients in South Korea: From Korean NHISS Claim Data.韩国初治患者抗高血压药物的处方模式：来自韩国国家健康保险服务索赔数据
Int J Hypertens. 2019 Aug 25;2019:4735876. doi: 10.1155/2019/4735876. eCollection 2019.
8
2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension.2018年韩国高血压学会高血压管理指南：第二部分——高血压的诊断与治疗
Clin Hypertens. 2019 Aug 1;25:20. doi: 10.1186/s40885-019-0124-x. eCollection 2019.
9
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).日本高血压学会高血压管理指南（JSH 2019）。
Hypertens Res. 2019 Sep;42(9):1235-1481. doi: 10.1038/s41440-019-0284-9.
10
Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases.随机临床试验荟萃分析用于观察性数据库分布式网络分析的经验教训。
Pharm Stat. 2019 Jan;18(1):65-77. doi: 10.1002/pst.1908. Epub 2018 Oct 25.